Abeona Therapeutics (NASDAQ:ABEO) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report issued on Monday, Marketbeat reports. The firm issued an outperform rating and a $19.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright upped their price target on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, April 30th. Alliance Global Partners reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Stifel Nicolaus lowered their target price on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Finally, Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.25.

Abeona Therapeutics Stock Performance

Shares of NASDAQ:ABEO opened at $6.44 on Monday. The firm has a market capitalization of $329.45 million, a PE ratio of -2.39 and a beta of 1.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The business has a 50-day moving average of $5.48 and a two-hundred day moving average of $5.57. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.11. As a group, research analysts forecast that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Insider Activity

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares in the company, valued at $6,478,439.16. This trade represents a 1.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Alvino sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $5.68, for a total value of $45,440.00. Following the sale, the director now owns 92,435 shares of the company’s stock, valued at approximately $525,030.80. This trade represents a 7.97% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,000 shares of company stock worth $177,700. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds have recently bought and sold shares of the business. OMERS ADMINISTRATION Corp grew its stake in Abeona Therapeutics by 11.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 7,155 shares in the last quarter. Twinbeech Capital LP acquired a new stake in Abeona Therapeutics during the 4th quarter valued at approximately $58,000. Northern Trust Corp grew its stake in Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Abeona Therapeutics during the 4th quarter valued at approximately $67,000. Finally, Cannon Global Investment Management LLC acquired a new stake in Abeona Therapeutics during the 1st quarter valued at approximately $67,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.